BridgeBio Pharma, Inc. — Director's Dealing 2020

Apr 3, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-04-01

Reporting Person: STEPHENSON BRIAN C (See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-04-01	Common Stock	S	3414	$26.0057	Disposed	334102	Direct
2020-04-01	Common Stock	S	2500	$26.8596	Disposed	331602	Direct
2020-04-01	Common Stock	S	1286	$27.7427	Disposed	330316	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019.

F2: Represents the weighted average sale price of the shares sold from $25.43 to $26.41 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3 and 4.

F3: Represents the weighted average sale price of the shares sold from $26.44 to $27.42 per share.

F4: Represents the weighted average sale price of the shares sold from $27.50 to $28.18 per share.